MacroGenics Q2 FY26 turns to net income of $19.52 million; revenue more than doubled to $32.83 million

Reuters2026/08/13 20:14

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MacroGenics swung to GAAP net income of $19.5 million in Q2 2026 from a net loss a year earlier.
Revenue more than doubled to $32.8 million, driven by a $24.5 million Sanofi regulatory milestone tied to U.S. TZIELD approval.
R&D expense edged down to $38.8 million; G&A fell to $7.9 million on lower personnel-related costs.
Sold GMP drug-substance manufacturing operations to Bora for a $122.5 million base price, receiving $119.6 million cash at closing.
Pro forma cash and marketable securities totaled $327 million, extending runway guidance through 2028; ESMO 2026 data planned for MGC026 and lorigerlimab.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MacroGenics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131605PRIMZONEFULLFEED9809876) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

MacroGenics Q2 FY26 turns to net income of $19.52 million; revenue more than doubled to $32.83 million

You may also like

Crypto prices